TSLA
Tesla
-- 248.710 NVDA
NVIDIA
-- 117.700 PLTR
Palantir
-- 90.960 MU
Micron Technology
-- 94.720 AAPL
Apple
-- 218.270 
NEWS
Invivyd to Present PEMGARDA™ (pemivibart) Data at Infectious Disease Week (IDWeek) 2024
Invivyd (Nasdaq: IVVD) announced upcoming presentations of pemivibart data from its Phase 1 and Phase 3 clinical trials at IDWeek 2024 in Los Angeles, October 16-19, 2024. The presentations include:
An oral presentation on clinical efficacy endpoints from the Phase 3 CANOPY Study
A poster on results from a Phase 1 first-in-human study
A poster on pharmacokinetics and serum virus neutralizing antibody titers following the 2nd dose in the Phase 3 CANOPY Trial
Robert Allen, Chief Scientific Officer at Invivyd, emphasized the importance of sharing this data as COVID-19 continues to pose a threat, particularly to immunocompromised individuals. The company will make the posters and presentation available on their website after the conference.
An oral presentation on clinical efficacy endpoints from the Phase 3 CANOPY Study
A poster on results from a Phase 1 first-in-human study
A poster on pharmacokinetics and serum virus neutralizing antibody titers following the 2nd dose in the Phase 3 CANOPY Trial
Robert Allen, Chief Scientific Officer at Invivyd, emphasized the importance of sharing this data as COVID-19 continues to pose a threat, particularly to immunocompromised individuals. The company will make the posters and presentation available on their website after the conference.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Mubi : please rest![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined")